Psychosomatic Medicine Faster Service from Outside North America
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wagner, J. A.
Right arrow Articles by Abbott, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagner, J. A.
Right arrow Articles by Abbott, G.
Related Collections
Right arrow Other Cardiovascular Medicine
Right arrow Depression
Right arrow Sexual Medicine: Female
Psychosomatic Medicine 68:80-86 (2006)
© 2006 American Psychosomatic Society


ORIGINAL ARTICLES

History of Major Depressive Disorder and Endothelial Function in Postmenopausal Women

Julie A. Wagner, PhD, Howard Tennen, PhD, George A. Mansoor, MD, FRCP (UK) and Gina Abbott, PhD

From the Department of Behavioral Sciences and Community Health (J.A.W., G.A.), Department of Community Medicine (H.T.), and Department of Medicine, Section of Hypertension (G.A.M.), the University of Connecticut Health Center, Farmington, CT.

Address correspondence and reprint requests to Julie Wagner, PhD, Department of Behavioral Sciences and Community Health MC3910, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT 06410. E-mail: juwagner{at}uchc.edu


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 
Objective: To determine whether history of depression is associated with endothelium-dependent flow-mediated dilation (FMD) in postmenopausal women.

Methods: Thirty-nine postmenopausal women with no known or suspected cardiovascular disease participated. Nineteen had a positive lifetime history of major depressive disorder, and 20 were never depressed. None were currently depressed, and all had been free of major depressive disorder and antidepressant medications for ≥1 year. History of depression was assessed with the Structured Clinical Interview for DSM-IV, enhanced by a modified version of the timeline follow-back method. Current depressive symptoms were measured with the Center for Epidemiological Studies Depression scale (CES-D). Brachial artery FMD was measured with ultrasound and calculated as percent dilation from baseline.

Results: After controlling for current subclinical depressive symptoms, ethnicity, hormone replacement therapy, and presence of the metabolic syndrome, previously depressed women showed significantly and clinically meaningful lower FMD than never depressed women. Controlling the same covariates, there was a dose-response relationship between number of depressive episodes and FMD. Examination of FMD means showed a significant negative correlation between number of depressive episodes and FMD.

Conclusion: In postmenopausal women, depression continues to show a negative relationship to endothelial functioning even after years of remission. This relationship is not accounted for by residual depressive symptoms. Implications pertain to exclusion of previously depressed persons from control groups in research exploring the relationship between depression and cardiovascular disease.

Key Words: depression • measurement • endothelial function • coronary heart disease • women • postmenopausal

Abbreviations: CHD = coronary heart disease; FMD = flow-mediated dilation; CES-D = Center for Epidemiological Studies Depression questionnaire; BMI = body mass index; SCID = Structured Clinical Interview for DSM-IV; TLFB = timeline follow-back; HRT = hormone replacement therapy.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 
Coronary heart disease (CHD) is the major cause of death for women after the age of 50 (1). In the US, for example, 1 in 9 women aged 45 to 64 has clinical CHD, and after age 65, the figure rises to 1 in 3 (2). Despite seemingly higher rates of CHD among men, it is a delay in the onset of the disease among women that is the greatest contributor to the sex difference (3). It is during the postmenopausal years that women lose cardioprotection.

Major depressive disorder is a risk factor for incident CHD (4), and women have higher rates of major depressive disorder than their male counterparts (5,6). Although less is known about depression as a risk factor for CHD in women and minorities relative to men and whites, the Women’s Health Initiative did show that depression is a risk factor for incident CHD in women specifically (7). It has been hypothesized that depression may exert its deleterious effects at least in part via endothelial dysfunction (8). Currently depressed persons show altered chemical markers of endothelial function and immune activation, inflammatory response, and coagulation (9–17). Functional alteration in the endothelium relates to impaired hyperemic response to experimental arterial occlusion (flow-mediated dilation, or FMD). Presently there are three controlled studies of current major depressive disorder and FMD, each of which showed that current depression or its symptoms were associated with attenuated brachial artery FMD (18–20), although the temporal direction of this association is not clear.

Far less is known about the effect of history of depression. Specifically, it is unknown whether endothelial dysfunction continues after the depressive episode resolves. Data from other areas of research suggest that this might be the case. In the Women’s Health Initiative, survival curves for those depressed and not depressed become more separate over time, indicating that the deleterious association between depression and vascular disease is not proximal to depression assessment (7). Major depressive disorder is associated with cellular alterations that remain abnormal in remission, thus creating risk for worse outcomes long after the depressive episode (21,22). This may help to explain why patients with a history of major depressive disorder before myocardial infarction have higher mortality than those who experience their first episode postinfarct (23). Certainly there are state-dependent depression effects which are perhaps even stronger than any effects that might be detected during depression remission. However, history of depression has been associated with health problems in middle-aged women, including physical symptoms (24), coronary and aortic calcification (25), and carotid plaque (26).

Moreover, we are unaware of any data relating endothelial function to duration of depression over the lifespan. Specifically, it is unknown whether a greater number of depressive episodes are related to more impairment in endothelial function. Major depressive disorder can be a chronic, progressive condition, with each episode increasing the likelihood of an additional episode and subsequent interepisode recovery periods of shorter duration with decreased symptom relief (6,27). It is possible that there is a "dose-response" relationship between depression and cardiovascular risk such that more depressive episodes and/or longer exposure to depression is associated with higher risk.

The purpose of this study was two-fold. Our primary goal was to determine whether the association between depression and endothelial function persists into depression remission among postmenopausal women. In order to do this, we did not study currently depressed women. Instead, we compared never depressed women to currently nondepressed women who had a history of major depressive disorder. Our secondary goal was to explore whether there was a dose-response relationship between number of depressive episodes and endothelial functioning. In addressing both goats, we took into account current depressive symptoms in order to isolate the effects of the depressive episodes.


    METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 
Participants
Participants were naturally postmenopausal women between 45 and 80 years of age. They were recruited between 2003 and 2005. Postmenopausal status was established by participant self-report of last menstrual cycle ≥1 year before enrollment. Exclusion criteria included current depressive disorder, known or suspected CHD (angina, angiography, positive stress test, heart failure, or major adverse cardiac event), stroke, peripheral vascular disease, diabetes mellitus, surgical menopause, current psychoactive medication, active substance abuse/dependence, impaired mental status, and current smokers. Current depressive disorder was selected as exclusion criteria in order to ensure that any effects of history of depression could not be better accounted for by current major depressive episode or current depressive symptoms. Current psychoactive drugs, including antidepressants, were selected because their effect on endothelial functioning is largely unknown. Known or suspected vascular disease was selected because we were interested in studying depression as a primary risk factor, i.e., as a risk factor for development of new-onset CHD in women without the disease. Smoking and diabetes were selected because they are strongly related to endothelial function (e.g., 28,29). Surgical menopause was selected because women who undergo double oophorectomy have hormonal alterations, either by virtue of hormone deficiency or replacement, that may affect their cardiovascular health (3). Women with a history of depression were deliberately oversampled. Women were recruited using newspaper advertisements, listserves, and state employee paycheck inserts.

Measures
Demographics were obtained via self-report questionnaire. A research nurse took a medical history which included self-reported age; smoking history; as well as use of lipid-lowering, antihypertensive, antioxidant, aspirin, and hormone replacement therapies (HRT). Women bring all medications with them to the study visit to decrease unreliability due to poor recall. Questionable data were confirmed with the participant’s physician. Caffeine consumption was measured via self-report as servings of coffee, tea, and caffeinated soda per typical day.

Presence of the metabolic syndrome was determined according to NCEP ATPIII criteria for women (30,31). Waist circumference was measured by the study nurse by taking measurements at the midpoint between the upper iliac crest and the lower costal margin in the midaxillary line. Blood pressure was measured per JNC-VII guidelines with manual sphygmomanometer by the research nurse. Body mass index (BMI) was calculated from weight and height data as weight in kilograms divided by height in meters squared. Weight in kilograms and height in centimeters are measured by the research nurse with calibrated equipment. Fasting plasma glucose is analyzed in the University of Connecticut’s hospital clinical lab with the Beckman Coulter LXI system. Physical activity was assessed via the Framingham Physical Activity Index, which provides self-reported physical activity during a typical 24-hour period (32).

Main Study Variables
Brachial artery FMD was assessed with ultrasound. Flow is increased by cuff occlusion of the forearm and then releasing the cuff. The method is repeated using an exogenous nitric oxide donor (nitroglycerine) to assess endothelium-independent activity. Images are captured on high-resolution videotape by a blinded technician and analyzed offline by a blinded observer in four stages. (a) Artery baseline diameter is obtained from five measurements at diastole in each of three frames. (b) Artery diameter during hyperemia is measured similarly on the 1-minute post hyperemia images. Reactive hyperemia is calculated and reported here as the percentage increase in brachial artery diameter from baseline.

Current depressive symptoms were measured with the Center for Epidemiological Studies Depression questionnaire (CES-D; 33). This widely used 20-item scale measures depressive symptoms during the preceding week. The scale has high internal consistency, test-retest reliability, and construct validity in both community and clinical samples (34,35).

History of depression was assessed using the Structured Clinical Interview for DSM-IV (SCID; 36). History of depression was measured as a dichotomous variable (yes versus no), and as a continuous variable (number of depressive episodes over the lifespan). Interrater and test-retest agreement in the "excellent" range (37) for presence or absence of current Axis I disorders is not unusual with the SCID (38). In order to enhance recall, we adapted the timeline follow-back (TLFB) for use in this study (39). TLFB is a measure of previous behavior widely used in behavioral studies. In our version of the TLFB interview, several memory aids were used to enhance recall (e.g., key dates and life events served as anchors for reporting behavior, and a visual timeline calendar was constructed with the participant to graphically represent this information). The TLFB has been used with various populations to study a variety of psychological phenomena (40–46). The TLFB has demonstrated high test-retest reliability, content validity, concurrent criterion validity, collateral (informants) validity, and construct validity in both general and clinical samples (47). Validity of the method is highest when the respondent is willingly engaged in the interview procedure, as were participants in our study (48).

SCID Reliability
Four doctoral-level psychologists assessed lifetime history of major depressive disorder using the SCID. Audiotapes of 12 randomly selected SCID administrations showed 94% interrater reliability for individual SCID items (range, 60% to 100%), 100% interrater reliability for presence/absence of past major depressive disorder, and 100% interrater reliability for number of past depressive episodes. It should be noted that although checking interrater reliability in this fashion accounts for interindividual scoring of data obtained by a single SCID administration, it does not account for potential interindividual differences in SCID administration.

Statistical Analyses
Analyses were conducted using SPSS version 12.0. In order to test the association between history of depression and FMD, group differences were analyzed using ANCOVA, with depression history treated as a dichotomous independent variable (yes versus no) and FMD as a continuous dependent variable. In order to test a dose-response relationship between number of depressive episodes and FMD, Pearson’s correlations and partial correlations were calculated.

Results of evaluations of assumptions revealed that FMD data were normally distributed both within and among depression history groups. According to guidelines of Tabachnick and Fidell (49), the ratio of cases to predictors was satisfactory. Inspection of the data revealed no outliers for predictors or FMD. Cronbach’s {alpha} for the CES-D was satisfactory, {alpha} = 0.74.

Selection of Covariates
{chi}2 showed no differences by depression status for ethnicity, education, income, smoking history, daily vitamins, daily aspirin, HRT, antihypertensives, lipid-lowering agents, or presence of the metabolic syndrome. Point biserial correlations showed no relationship between history of depression and age, BMI, waist circumference, physical activity, systolic BP, diastolic BP, or caffeine consumption. The point biserial correlation between history of depression and CES-D scores was significant, r = 0.48, *p < .01. Based on these results and review of relevant literature, and to control for current levels of distress, CES-D scores were entered as a covariate (20).

In addition to CES-D scores, we also investigated neuroticism as an indicator of current distress using the neuroticism subscale of the NEO (50–52). Zero-order Pearson correlations revealed no relationship between neuroticism and FMD. Point biserial correlation showed a positive association between history of depression and NEO scores, r = 0.34, *p < .05. Inclusion of neuroticism as a covariate did not change the direction or significance of any of our findings, so results are reported without neuroticism as a covariate.

Looking at the sample as a whole, zero-order Pearson’s correlations showed no significant relationship between FMD and age, BMI, caffeine intake, physical activity, waist circumference, or CES-D scores. ANOVA showed no group differences in FMD by ethnicity. Point biserial correlation showed no relationship between FMD and antihypertensive agents, lipid-lowering agents, daily aspirin, daily vitamins, metabolic syndrome, smoking history, or HRT. Based on review of literature with postmenopausal women, ethnicity (53) and HRT (20) were entered as covariates. Based on a broader review of the literature, metabolic syndrome was entered as a covariate because it is a single measure that incorporates adiposity, glucose dysregulation, blood pressure, and lipids, all of which have been linked to endothelial function.

Procedures
The following procedure was approved by the University of Connecticut Health Center IRB. On day 1, a psychologist and study nurse met the participant at the University of Connecticut Health Center general clinical research center. After obtaining informed consent, the nurse completed the medical history and brief physical examination, the psychologist administered the SCID, and the participant completed the Framingham Physical Activity questionnaire and the CES-D. The participant was instructed how to prepare for day 2, which typically occurred 1 week later. For 24 hours before day 2, women refrained from exercise and high-fat foods, lipid-lowering and antihypertensive medications, as well as aspirin, vitamins, and caffeine. For 12 hours before day 2, women fasted. On the morning of day 2, a blood sample was obtained, and the participant completed the brachial artery FMD study, was served breakfast, and was financially compensated $75 for participation.

Arterial ultrasound study of endothelium-dependent FMD was performed according to the 2002 guidelines set forth by the International Brachial Artery Reactivity Task Force (54). The procedure took place in a temperature-controlled room (22°C) with continuous EKG tracing. Patients rested supine for 10 minutes. Blood pressure and heart rates were measured every 3 minutes in the free arm. The dominant arm was used for the study and was immobilized supine. A 12-MHz linear array transducer was used. The studies were divided into parts A and B. Part A: Longitudinal diastolic gated images of the brachial artery were obtained above the elbow, and a straight segment was used for image capture. Transducer beam was placed perpendicular to the posterior wall intimal surface. Baseline images were taken for 20 seconds, as well as diastole-gated images (five cycles). Pulsed flow systolic Doppler velocities were measured at the center of the vessel, with the transducer at 60 to 70 degrees. The exact position of the transducer was measured from the elbow and from the medial and lateral epicondyles for the second study. Part B: A blood pressure cuff was placed distal to the study site and inflated 10 mm Hg above systolic blood pressure for 5 minutes and then released. Doppler systolic blood flow was taken at 1 and 2 minutes, and artery images were repeated at 30 and 60 seconds after deflation. After a 20-minute period of rest, a repeat baseline study was obtained, followed by measurements 3 minutes after sublingual nitroglycerine 0.3 mg.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 
Participant Characteristics
For the whole sample, participants were on average 61 years of age, married (67%), and white (92%). The majority (89%) reported some post–high school education (89%) and earned over $60,000 per year (66.6%). For the whole sample, current depressive symptoms were relatively low, with an average CES-D score of 5.5. See Table 1 for descriptives by depression history.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Descriptive Statistics

 

In women with a history of depression, the average age of onset of major depressive disorder was 36 years, and 10 years had passed since remission of the most recent episode. The majority had experienced recurrent major depressive episodes (69%). By design, all had been free of major depression and antidepressant medication for at least 12 months. See Table 2 for depression descriptives.


View this table:
[in this window]
[in a new window]
 
TABLE 2. History of Depression Descriptive Statistics

 

History of Depression
A one-way ANCOVA was performed with previous major depressive disorder (yes/no) as the independent variable and FMD as the dependent variable. As outlined previously, covariates were CES-D scores, ethnicity, HRT, and presence of the metabolic syndrome. Previously depressed women demonstrated poorer dilation (M = 4.4%) than never depressed women (M = 11.2%), F (5, 39) = 4.83, *p < .05. None of the covariates were significantly associated with FMD. A one-way ANOVA with nitroglycerine-induced endothelium-independent FMD as the dependent variable showed no significant difference by history of depression.

Dose-Response Relationship Between Exposure to Depression and FMD
Zero-order Pearson’s correlation between FMD and number of depressive episodes was significant, r = –0.34, *p < .05. Examination of mean FMD scores suggests a dose-response relationship between number of depressive episodes and FMD, zero episodes M = 10.3%, SD = 0.02, one episode M = 7.5%, SD = 0.03, two episodes M = 5.0%, SD = 0.03, and three episodes M = 2.6%, SD = 0.04. Adjusting for CES-D scores, ethnicity, HRT, and presence of the metabolic syndrome did not attenuate this relationship, partial r = –0.36, *p < .05. Examination of adjusted mean FMD scores continued to suggest a dose-response relationship between number of depressive episodes and FMD, zero episodes M = 11.0%, 1 episode M = 6.0%, two episodes M = 4.4%, and three episodes M = 2.6%.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 
This study investigated the association between history of depression and endothelium-dependent FMD in postmenopausal women. Results indicate that history of depression, even in full remission, is associated with impaired FMD. Not only were the women in our sample in complete remission but they had been free from major depressive disorder for at least 12 months and for an average of 10 years. This suggests that depression continues to be related to endothelial dysfunction for years after depression remission.

The relationship between history of depression and FMD held even when current depressive symptoms were statistically controlled. This suggests that history of depression does not continue to influence the vasculature simply or solely via residual depressive symptoms. In fact, both the previously depressed and the never depressed women in our sample showed relatively low CES-D scores. This low level of depressive symptoms may account for our finding that depressive symptoms were not related to FMD, which is in contrast to other reports (20). One might expect that a group of previously depressed women with elevated residual depressive symptoms would show even more attenuated FMD.

We also observed a dose-response effect for the number of depressive episodes on FMD. Increasing depressive episodes was associated with greater endothelial dysfunction. Our results complement reports of impaired FMD in currently depressed participants (18–20). They also complement reports of cardiovascular effects of depression history in middle-aged women (25,26). To our knowledge, prior research has not examined the impact of depression history on endothelium-dependent FMD.

The differences observed in this study are clinically meaningful. Although the exact value of FMD that represents a normal response has not been established (54), a cutoff of >8% has been proposed (55,56). When using this cutoff, participants in this sample who were never depressed showed a normal response, whereas those with even one depressive episode showed an abnormal response.

Furthermore, the increasing decrements in FMD with each successive depressive episode were clinically meaningful. Very small group differences in FMD, on the order of 2%, are predictive of future cardiac events (55,57,58). We observed decreases of similar magnitude with each additional depressive episode. However, our sample size prevents us from concluding whether the differences in FMD between each episode are reproducible. A study is currently under way to establish the reliability of the differences between episodes. Furthermore, given the extra burden involved in collecting number of depressive episodes relative to presence/absence of depression history, this approach cannot be recommended for routine assessment until it is confidently demonstrated that number of depressive episodes yields added predictive power. Moreover, the range of number of episodes was not large in our sample, with the highest being three episodes. Therefore we cannot determine whether and at what point a floor effect might be observed with additional episodes. It is also unknown whether there is a clinical threshold for FMD. Perhaps once FMD reaches a certain degree of impairment, any addition loss of FMD makes little or no difference in prediction of subsequent cardiac events. These questions can only be answered with larger samples and prospective designs.

Implications
Our findings regarding history of depression have implications for determination of appropriate comparison groups in cardiovascular depression research, and suggest that investigating only current depression as a binary phenomenon may be inadequate. First, if one ignores history of depression and only measures current depression, those who are not currently depressed but who have experienced a previous depressive episode may be misclassified into a group thought to be free from the effects of depression. Studies may find a stronger effect for current depression if the comparison group consists of never depressed participants.

Second, measuring only current depression does not account for any residual subclinical depressive symptoms in nondepressed participants with a history of depression. The temporal course of major depression has changed conceptually in recent years from being viewed as a relapsing remitting illness to a chronic illness with varying levels of symptomatology (59). It is known that previously depressed persons have elevated depressive symptoms long after they no longer meet criteria for the disorder (60,61). It is also known that subclinical depressive symptoms are associated with cardiovascular perturbations (62). Studies that do not account for subclinical symptoms in previously depressed persons cannot determine whether effects are due to the previous depressive episode per se, any lingering depressive symptoms, or a combination of the two.

Third, measuring only current depression assumes that those who are currently depressed are experiencing the effects of current depression only. Over the course of the depressive illness (27), patients are thought to experience sensitization to the state of depression, referred to as the "kindling effect" (63–65). Because modal age of first depressive episode is in young adulthood (66), this "kindling" effect can be reasoned backwards, i.e., that a late-middle-aged woman with a major depressive disorder is likely to have had a prior depressive episode or several episodes. To the extent that this is the case, studies that find an effect for current depression, especially in older participants, may actually be capturing the effect of both the current episode and past episodes.

Fourth, measuring only current depression does not account for duration of exposure to depression over the lifespan. Although our findings are limited by sample size, they suggest the importance of accounting for duration of depression over the lifespan.

Limitations and Future Directions
The sample size was small compared with some (20), but not all (19), reports of FMD and depression, possibly leading to Type II errors in detection of differences between groups on covariates. The number of women within each category of depressive episodes was also small, and there was a restricted range in the observed number of depressive episodes (i.e., 0–3). Future studies should employ larger samples with a greater range of number of episodes, and greater representation within each number of depressive episodes. This study employed only postmenopausal women who were primarily white and wealthy, thus limiting its generalizability. Future studies should investigate more diverse samples of men and women. Additionally, the retrospective depression assessment introduces three problems. First, it does not address directionality of the association. It is possible that endothelial dysfunction causes behavior that either is, or presents similar to, depression. Second, an additional unknown and unmeasured variable may account for the association between history of depression and FMD. For these reasons, prospective studies would be ideal, although they require considerable resources, given that onset of first depressive episode tends to occur in the second or third decade of life, menopause several decades later, and incident CHD even later. Third, all self-report and retrospective data are subject to some degree of unreliability due to participant deception, bias, and poor recall. There was no benefit for participants in our study to deceive the interviewer. Bias is most likely a problem when current mood disturbance colors recollection (67,68), and our participant were all free of current depression. Recall was enhanced with the TLFB method. In these ways, we minimized the unavoidable limitations of self-report retrospective data.


    CONCLUSIONS
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 
In postmenopausal women, major depressive disorder continues to be associated with endothelial dysfunction even years after the episode resolves. There also appears to be a dose-response relationship, whereby increasing number of depressive episodes is associated with decreased endothelial function. These results provide further data to suggest that depression may increase risk for CHD in part via endothelial dysfunction, although the temporal direction of this association is still unknown. Results also imply that careful attention to how comparison groups are composed is necessary to draw valid conclusions from depression research. Limitations of this study can be improved on with prospective studies of larger, more heterogeneous samples.


    NOTES
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 

Supported by grants from the University of Connecticut Center for Interdisciplinary Research in Women’s Health, the American Heart Association, and the University of Connecticut Health Center General Clinical Research Center.

DOI:10.1097/01.psy.0000195868.68122.9e


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 NOTES
 REFERENCES
 

  1. Wenger N. Coronary heart disease: an older woman’s major health risk. BMJ 1997;80:66H–8.
  2. Wenger N, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993;329:247–56.[Free Full Text]
  3. Meihlan E. Sex steroid hormonal influences on coronary artery disease. In: Ness R, Kuller L, eds. Health and Disease among Women: Biological and Environmental Influences. New York: Oxford University Press; 1999:155–82.
  4. Lett H, Blumenthal J, Babyak M, Sherwood A, Strauman T, Robins C, Newman MF. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305–15.[Abstract/Free Full Text]
  5. Kessler R, McGonagle K, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8–19.[Abstract]
  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
  7. Wassertheil-Smoller S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B, Robbins J, Aragaki A, Dunbar-Jacob J. Depression and cardiovascular sequelae in postmenopausal women: the women’s health initiative (WHI). Arch Int Med 2004;164:289–98.[Abstract/Free Full Text]
  8. Strike PC, Steptoe A. Psychosocial factors in the development of coronary artery disease. Prog Cardiovasc Dis 2004;46:337–47.[CrossRef][Medline]
  9. Lesperance F, Frasure-Smith N, Theroux P, Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry 2004;161:271–7.[Abstract/Free Full Text]
  10. Ford D, Erlinger T. Depression and C-reactive protein in US adults: data from the third national health and nutrition examination survey. Arch Intern Med 2004;164:1010–4.[Abstract/Free Full Text]
  11. Tuglu C, Kara S, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003;170:429–33.[CrossRef][Medline]
  12. Penninx B, Beekman A, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, van Tilburg W. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001;58:221–7.[Abstract/Free Full Text]
  13. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, Kirchner H. Inflammatory markers in major depression and melancholia. J Affect Disord 2001;63:93–102.[CrossRef][Medline]
  14. Licinio J, Wong M. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999;4:317–27.[CrossRef][Medline]
  15. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Melledo JM. Decreased platelet nitric oxide synthase activity and plasma nitrate oxide metabolites in major depressive disorder. Biol Psychiatry 2004;56:129–34.[CrossRef][Medline]
  16. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med 2003;65:347–56.[Abstract/Free Full Text]
  17. von Kanel R, Mills PJ, Fainman C, Dimsdale JE. Effects of psychobiological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosom Med 2001;63:531–44.[Abstract/Free Full Text]
  18. Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol 2001;88:196–8.[CrossRef][Medline]
  19. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart 2002;88:521–3.[Abstract/Free Full Text]
  20. Harris KF, Matthews KA, Sutton-Tyrrell K, Kuller LH. Associations between psychological traits and endothelial function in postmenopausal women. Psychosom Med 2004;65:402–9.
  21. Post R. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999–1010.[Abstract/Free Full Text]
  22. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically health women with recurrent major depressive depression. J Neurosci 1999;19:5034–43.[Abstract/Free Full Text]
  23. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1999;58:99–110.
  24. Bromberger JT, Kravitz HM, Wei HL, Brown C, Youk AO, Cordal A, Powell LH, Matthews KA. History of depression and women’s current health and functioning during midlife. Gen Hosp Psychiatry 2005;27:200–8.[CrossRef][Medline]
  25. Agatisa PK, Matthews KA, Bromberger JT, Edmudowicz D, Change YF, Sutton-Tyrrell K. Coronary and aortic calcification in women with a history of major depression. Arch Intern Med 2005;165:1229–36.[Abstract/Free Full Text]
  26. Jones DJ, Bromberger JT, Sutton-Tyrrell K, Matthews KA. Lifetime history of depression and carotid atherosclerosis in middle-aged women. Arch Gen Psychiatry 2003;60:153–60.[Abstract/Free Full Text]
  27. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000;157:229–33.[Abstract/Free Full Text]
  28. Esen AM, Barutcu I, Acar M, Degirmenci B, Kaya D, Turkmen M, Melek M, Onrat E, Esen OB, Kirma C. Effect of smoking on endothelial function and wall thickness of brachial artery. Circ J 2004;68:1123–6.[CrossRef][Medline]
  29. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 2005;28:702–7.[Abstract/Free Full Text]
  30. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. National Institutes of Health; 2001. NIH Publication 01-3670.
  31. Piche M, Weisnagel S, Nadeau A, Corneau L, Bergeron J, Lenieux S. Comparison of two proposed definitions of the metabolic syndrome in postmenopausal women not receiving hormonal replacement therapy (abstract). Diabetes 2004;750-P:A185.
  32. Kannel W, Sorlie P. Framingham physical activity index. In: Pereira MA, Fitzgerald SJ, Gregg EW, Joswiak ML, Ryan WJ, Suminski RR, Utter AC, Zmuda JM, eds. A collection of physical activity questionnaires for health-related research. Med Sci Sports Exercise Supp 1997;29:S33–5.
  33. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. J Appl Psychol Meas 1977;1:385–401.[CrossRef]
  34. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med 1994;10:77–84.[Medline]
  35. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977;106:203–14.[Abstract/Free Full Text]
  36. First MB, Spitzer RL, Gibbon R, Williams JBW. Structured Clinical Interview from DSM-IV, Axis Disorders, Patient Edition (SCID-I/P Version 2.0, 8/98 revision). New York: New York State Psychiatric Institute; 1998.
  37. Fleiss J. Statistical Methods for Rates and Proportions. 2nd ed. New York: Wiley; 1981.
  38. Skre I. High interrater reliability for the Structured Clinical Interview for DSM Axis 1. Acta Psychiatr Scan 1991;84:167–73.[Medline]
  39. Sobell L, Sobell M. Alcohol Timeline Followback User’s Manual. Toronto: Addiction Research Foundation; 1995.
  40. Project MATCH Research Group. Rationale and methods for a multisite clinical trial matching patients to alcoholism treatment. Alcohol Clin Exp Res 1993;17:1130–45.[Medline]
  41. Midanik LT, Hines AM, Barrett DC, Paul JP, Crosby GM, Stall RD. Self-reports of alcohol use, drug use and sexual behavior: expanding the timeline follow-back technique. J Stud Alcohol 1998;59:681–9.[Medline]
  42. Crosby GM, Stall RD, Paul JP, Barrett DC, Midanik LT. Condom use among gay/bisexual male substance abusers using the timeline follow-back method. Addict Behav 1996;21:249–57.[CrossRef][Medline]
  43. Bardone AM, Krahn DD, Goodman BM, Searles JS. Using interactive voice response technology and timeline follow-back methodology in studying binge eating and drinking behavior: different answers to different forms of the same question? Addict Behav 2000;25:1–11.[CrossRef][Medline]
  44. Weinstock J, Whelan JP, Meyers AW. Behavioral assessment of gambling: an application of the timeline follow-back method. Psychol Assess 2004;16:72–80.[CrossRef][Medline]
  45. Stephens RS, Babor TF, Kadden R, Miller M, Marijuana Treatment Project Research Group. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction 2002;97:109–24.
  46. Hersh D, Mulgrew C, Van Kirk J, Kranzler H. The validity of self-reported cocaine use in two groups of cocaine abusers. J Consult Clin Psychol 1999;67:37–42.[CrossRef][Medline]
  47. Sobell LC. Alcohol Timeline Followback (TLFB) [National Institute on Alcohol Abuse and Alcoholism (NIAAA) Web site]. Available at: http://www.niaaa.nih.gov/publications/Assesing%20Alcohol/InstrumentPDFs/13_TLFB.pdf. Accessed June 29, 2005.
  48. Vinson D, Reidinger C, Wilcosky T. Factors affecting the validity of a timeline follow back interview. J Stud Alcohol 2003;64:733–40.[Medline]
  49. Tabachnick B, Fidell L. Using Multivariate Statistics. 3rd ed. New York: Harper Collins College Publishers; 1996.
  50. Costa PT, McCrae RR. NEO PI-R Professional Manual: Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI). Odessa, FL: Psychological Assessment Resources, Inc; 1992.
  51. Scandell DJ. Development and initial validation of validity scales for the NEO-Five Factor Inventory. Pers Individ Dif 2000;29:1153–62.[CrossRef]
  52. Tokar DM, Fischer AR, Snell AF, Harik-Williams N. Efficient assessment of the five-factor model of personality: structural validity analyses of the NEO Five-Factor Inventory (Form S). Measure Eval Counsel Dev 1999;32:14–30.
  53. Loehr LR, Espeland MA, Sutton-Tyrrell K, Burke GL, Crouse JR 3rd, Herrington DM. Racial differences in endothelial function in postmenopausal women. Am Heart J 2004;148:606–11.[CrossRef][Medline]
  54. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–65.[Abstract/Free Full Text]
  55. Gokce N, Keaney JF, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769–75.[Abstract/Free Full Text]
  56. Gaenzer H, Neumayr G, Marschang P, Sturm W, Kirchmair R, Patsch FR. Flow-mediated vasodilation of the femoral and brachial artery induced by exercise in health nonsmoking and smoking men. J Am Coll Cardiol 2001;38:1313–9.[Abstract/Free Full Text]
  57. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003;42:1037–43.[Abstract/Free Full Text]
  58. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003;108:2093–8.[Abstract/Free Full Text]
  59. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long term outcome. J Affect Disord 2004;80:135–44.[CrossRef][Medline]
  60. Fawcett J. Antidepressants: partial response in chronic depression. Br J Psychiatry Suppl 1994;26:37–41.
  61. Bothwell R, Scott J. The influence of cognitive variables on recovery in depressed inpatients. J Affect Disord 1997;43:207–12.[CrossRef][Medline]
  62. Rowan PJ, Haas D, Campbell JA, Maclean DR, Davidson KW. Depressive symptoms have an independent, gradient risk for coronary heart disease incidence in a random, population-based sample. Ann Epidemiol 2005;15:316–320.[CrossRef][Medline]
  63. Segal ZV, Williams JM, Teasdale JD, Gemar M. A cognitive science perspective on kindling and episode sensitization in recurrent affective disorder. Psychol Med 1996;26:371–80.[Medline]
  64. Kendler K, Thornton L, Gardener C. Stressful life event and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry 2000;157:1243–51.[Abstract/Free Full Text]
  65. Kendler K, Thornton L, Gardner C. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry 2001;158:582–6.[Abstract/Free Full Text]
  66. Bijl RV, De Graaf R, Ravelli A, Smit F, Vollebergh WA. Netherlands Mental Health Survey and Incidence Study: gender and age-specific first incidence of DSM-III-R psychiatric disorders in the general population. Soc Psychiatry Psychiatr Epidemiol 2002;37:372–9.[CrossRef][Medline]
  67. Blaney P. Affect and memory: a review. Psychol Bull 1986;99:229–46.[CrossRef][Medline]
  68. Bower G. Mood and memory. Am Psychol 1981;36:129–48.[CrossRef][Medline]



This article has been cited by other articles:


Home page
CirculationHome page
G. A. Wellenius, K. J. Mukamal, A. Kulshreshtha, S. Asonganyi, and M. A. Mittleman
Depressive Symptoms and the Risk of Atherosclerotic Progression Among Patients With Coronary Artery Bypass Grafts
Circulation, May 6, 2008; 117(18): 2313 - 2319.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
S. Herbst, R. H. Pietrzak, J. Wagner, W. B. White, and N. M. Petry
Lifetime Major Depression is Associated With Coronary Heart Disease in Older Adults: Results From the National Epidemiologic Survey on Alcohol and Related Conditions
Psychosom Med, October 1, 2007; 69(8): 729 - 734.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wagner, J. A.
Right arrow Articles by Abbott, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagner, J. A.
Right arrow Articles by Abbott, G.
Related Collections
Right arrow Other Cardiovascular Medicine
Right arrow Depression
Right arrow Sexual Medicine: Female


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS